至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.

Adv Sci (Weinh). 2019; 
Pesarrodona Mireia,Jauset Toni,Díaz-Riascos Zamira V,Sánchez-Chardi Alejandro,Beaulieu Marie-Eve,Seras-Franzoso Joaquin,Sánchez-García Laura,Baltà-Foix Ricardo,Mancilla Sandra,Fernández Yolanda,Rinas Ursula,Schwartz Simó,Soucek Laura,Villaverde Antonio,Abasolo Ibane,Vázquez Es
Products/Services Used Details Operation
Gene Synthesis FN-p31-H6 and Omo-FN-H6 genes, together with the biologically inactive control gene FN-GFP-H6 and nontargeted GFP-H6 control gene, were provided by GenScript (Hong Kong, China). Get A Quote

摘要

Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44 tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.

关键词

biofabrication,cancer therapy,functional amyloids,inclusion bodies,protein drug rel